U.S. markets closed
  • S&P 500

    3,998.84
    -72.86 (-1.79%)
     
  • Dow 30

    33,947.10
    -482.78 (-1.40%)
     
  • Nasdaq

    11,239.94
    -221.56 (-1.93%)
     
  • Russell 2000

    1,840.22
    -52.62 (-2.78%)
     
  • Crude Oil

    77.46
    +0.53 (+0.69%)
     
  • Gold

    1,782.60
    +1.30 (+0.07%)
     
  • Silver

    22.45
    +0.04 (+0.17%)
     
  • EUR/USD

    1.0512
    +0.0014 (+0.14%)
     
  • 10-Yr Bond

    3.5990
    +0.0930 (+2.65%)
     
  • GBP/USD

    1.2208
    +0.0014 (+0.11%)
     
  • USD/JPY

    136.3630
    -0.3220 (-0.24%)
     
  • BTC-USD

    17,010.67
    -107.61 (-0.63%)
     
  • CMC Crypto 200

    401.92
    -9.30 (-2.26%)
     
  • FTSE 100

    7,567.54
    +11.31 (+0.15%)
     
  • Nikkei 225

    27,778.65
    -41.75 (-0.15%)
     

Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference

BALA CYNWYD, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the Guggenheim Virtual Neuro/Immunology Conference taking place November 15 – 16, 2021.

About Larimar Therapeutics

Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569

Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715